Brief: Arcutis Announces Health Canada Approval of ZORYVE® (Roflumilast) Foam 0.3% to Treat Seborrheic Dermatitis in Individuals 9 Years of Age and Older
18/10/2024 13:22
Oct 18 (Reuters) - Arcutis Biotherapeutics Inc ARQT.O :
* ARCUTIS ANNOUNCES HEALTH CANADA APPROVAL OF ZORYVE®
(ROFLUMILAST) FOAM 0.3% TO TREAT SEBORRHEIC DERMATITIS IN
INDIVIDUALS 9 YEARS OF AGE AND OLDER
Source text for Eikon: ID:nGNX1zjVBc
Further company coverage: ARQT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Arcutis Biotherapeutics
See all newsBrief: Arcutis Biotherapeutics reports inducement grants under Nasdaq listing rule 5635(C)(4
Arcutis Q1 product revenue rises 65% yr/yr, net loss narrows
Brief: Arcutis Announces Promotion Of MAS Matsuda To Executive Vice President And Chief Legal Officer To Support Next Phase Of Growth
Brief: Arcutis Begins Enrolling Phase 1A/1B Study Evaluating Arq-234, A Cd200r Agonist, In Healthy Volunteers And Adults With Atopic Dermatitis
Brief: Arcutis Biotherapeutics Inc Files For Mixed Shelf